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Abstract 
Introduction: Stimuli-responsive nanomaterials for cancer therapy have attracted much 
interest recently due to their potential for improving the current standard of care. 
Different types of inorganic nanoparticles are widely employed for the development of 
these strategies, but in some cases safety concerns hinder their clinical translation. This 
review aims to provide an overview of the challenges that inorganic nanoparticles face 
regarding their stability, toxicity and biodegradability, as well as the trategies that have 
been proposed to overcome them. 
Areas covered: The available information about the in vitro and in vivo biocompatibility, 
as well as the biodegradability of the following nanoparticles is presented and 
discussed: superparamagnetic iron oxide nanoparticles, gold nanoparticles, graphene 
and mesoporous nanoparticles made of silicon or silicon oxide. The toxicology of 
inorganic nanoparticles is greatly affected by many physicochemical parameters, and 
their surface modification emerges as the main intervention to improve their 
biocompatibility and tailor their performance for specific biomedical applications.   
Expert opinion: Even though many different studies have been performed regarding 
the biological behavior of inorganic nanoparticles, long-term in vivo data is still scarce, 
limiting our capacity to evaluate the proposed nanomaterials for clinical use. The role of 
biodegradability in different therapeutic contexts is also discussed. 
Keywords: Inorganic nanoparticles, mesoporous silica nanoparticles. nanomedicine, 
nano-toxicology, superparamagnetic iron oxide nanoparticles. 
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Article highlights 
- A series of inorganic nanoparticles have become fundamental tools in the 
development of stimuli-responsive nanoparticles for oncological treatment, 
making necessary their nano-toxicological evaluation.  
- SPION have been employed as drug delivery systems and magnetically triggered 
heaters. These nanoparticles present potential toxicity by the production of 
radical oxidative species but this undesired property has been diminished by 
tuning their size and/or coating their surface with different moieties. 
- GNP present unique optical properties which have been exploited for the 
production of hyperthermia seeds triggered by near-infrared radiation and 
imaging agents in combination with drug delivery agents. Their biocompatibility is 
excellent but they are barely degraded in physiological conditions. Therefore, 
their potential toxicity should be evaluated in long time assays. 
- Graphene has been thoroughly studied for drug and gene delivery, biosensing 
and imaging. Some studies have shown potential toxicity in physiological and 
pathological conditions, although the chemical modification and surface coating 
with different polymers can improve its biocompatibility profile. 
- Mesoporous particles made of silicon or silica present many advantages as drug 
delivery systems. Their biodegradability can be controlled by modifying a series 
of physicochemical parameters, which enables tailoring these materials for 
specific biomedical applications and preventing their long-term bioaccumulation.  
 
1. Introduction 
Nanoparticle use for cancer treatment has attracted significant attention, and several 
products are already approved for clinical use.[1] The main rationale for the 
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development of this discipline was the enhanced permeability and retention (EPR) 
effect.[2] The EPR effect describes the capacity of macromolecules and nanoparticles 
to extravasate and be retained in solid tumors due to their impaired vascular network. 
This preferential accumulation in cancerous tissues was expected to drastically improve 
the therapeutic efficacy while also greatly decreasing the dreaded side effects of 
traditional chemotherapeutic treatments in oncology. However, the main advantages of 
the nano-formulations employed in the clinic has been a moderate improvement in their 
toxicological profile, many times due to the possibility of avoiding toxic excipients that 
were being used prior to the development of these formulations.[1] Nanomaterials that 
can respond to changes in their environment materials have been proposed to 
overcome some of the limitations of the nano-drug delivery systems (nano-DDS) 
currently employed in the clinic, and some strategies have already entered into clinical 
evaluation.[3,4] These stimuli-responsive materials can react when exposed to either 
internal physiopathological factors or externally-induced changes, and their design and 
production has become an extremely active area of research. Different types of 
responses can be triggered by the stimulus, from releasing a drug (the most common 
strategy) to inducing tissue extravasation or cell uptake.[5–9] In the context of 
developing stimuli-responsive materials, a series of inorganic nanostructures have 
emerged as fundamental for this task.  
We believe that among the materials that can be highlighted, especial attention can be 
directed upon superparamagnetic iron oxide nanoparticles (SPION), gold nanoparticles, 
graphene and mesoporous nanoparticles made of silicon or silicon oxide (silica). SPION 
have become key components in the development of magnetic-responsive 
nanomaterials due to their capacity of inducing a temperature increase when exposed 
to alternating magnetic fields.[10] On the other hand, gold nanoparticles can also 
increase the surrounding temperature when stimulated with light in the appropriate 
wavelength, and are therefore very used in light-responsive nano-DDS.[11] Graphene 
shows a large surface area, since all of its atoms are exposed on its surface, which 
enables binding various molecules for drug and gene delivery. The high near-infrared 
(NIR) absorbance of nano-graphene also enables its use for photothermal therapy, and 
for developing light-responsive nanosystems.[12] Finally, the porous structure of 
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mesoporous silicon and silica nanoparticles (with very large surface areas) can act as a 
drug reservoir, and when different gatekeepers are grafted on the nanoparticle surface, 
the release of the loaded drugs can be postponed until the desired stimulus is 
present.[13] A particular type of this kind of materials, lipid bilayer-coated mesoporous 
silica nanoparticles (often called protocells) can also be highlighted as particularly 
promising, and will also be discussed here.[14] 
When considered collectively, inorganic nanoparticles present several common 
characteristics that make them promising therapeutic agents.[15,16] Among them, we 
can point out their physicochemical stability, which will enable successful protection of 
loaded drugs throughout their journey in the body, and also enabling a long shelf-life, 
which might be important for their clinical implementation. They are also generally easy 
to obtain in a finely-tunable manner, allowing us to optimize their size, shape and 
surface properties for particular medical conditions, administration routes or to formulate 
a specific drug. Despite the great promise that all of these nanoparticle types have for 
the development of therapeutic formulations, a common complaint presented against 
their use is the lack of certainty about the toxicological behavior of these inorganic 
structures.[15,16] The main safety concerns can derive from direct cell toxicity induced 
by the particles, potential nanoparticle aggregation (which can lead to vascular 
obstruction), long-term bioaccumulation, hemolytic activity and immune recognition and 
toxicity. Several strategies have been adopted to tackle these issues, for example, by 
chemically customizing the nanoparticle surface to modify their interaction with other 
nanoparticles or with the biological environment, decreasing the risk of aggregation, 
immune recognition of hemolysis. Although it has already been highlighted that 
inorganic nanoparticles present high physicochemical stability, the nanoparticle matrix 
can in some cases be modified to enable biodegradation or excretion, to prevent long-
term bioaccumulation of the nanotherapeutic agents. The primary objective of this 
article is to provide an overview of the existing data regarding the stability, toxicity and 
biodegradability of these inorganic nanostructures, and presenting the strategies 
developed to improve these parameters as well as presenting our perspective on the 
current developments and future needs in this area. 
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2. Superparamagnetic iron oxide nanoparticles (SPION) 
Iron oxide nanoparticles have received huge attention for the treatment of solid tumors 
due to their superparamagnetic properties that produce heat under the application of 
alternative magnetic fields.[10] The temperature increase achieved by the nanoparticle 
accumulated in the diseased tissue followed by the exposition to magnetic field cause a 
significant cellular stress, by itself or in combination with chemotherapy, which provoke 
the destruction of the tumoral mass. That is the basics of the so-called magnetic 
hyperthermia therapy.[17] These particles can be easily synthesized following different 
methods such as co-precipitation, thermal decomposition or solvothermal synthesis, 
among others.[18] SPION have been recognized as biocompatible materials showing 
scarce cytotoxicity in in vitro cell culture studies at concentrations below 100 µg·mL-
1.[19] However, the toxicity of these particles is strongly dependent of their surface 
properties and therefore can be modulated by the type of coating or functional groups 
on their surface. Ankamwar et al. reported that Fe3O4 nanoparticles coated with 
tetramethylammonium 11-aminoundecanoate cause significant toxicity in different cell 
populations at concentrations higher than 10 µg·mL-1.[20] Therefore, it is necessary to 
carefully design the biocompatible coatings to allow the safe use of these particles. The 
cell toxicity caused by SPION is mainly associated to their capacity to generate radical 
oxidative species (ROS) such as superoxide, hydroxyl radicals or hydrogen peroxide 
through Fenton reaction (H2O2+Fe2+→Fe3++HO−+HO·).[21] The generation of ROS can 
be catalysed on the surface of the nanoparticle or by iron leached to the media. ROS 
harm cells through different mechanisms as lipid peroxidation which induce membrane 
malfunction, mitochondrial injury, DNA disruption and the oxidation of key proteins that 
provoke multiple alterations in the normal cell cycle. ROS generation particularly affects 
to organs that present high mitochondrial activity that produces O2- and H2O2 as heart or 
liver making these tissues more sensitive to iron toxicity.[22]  Sung et al. have reported 
that SPION toxicity is strongly related with their degradation rate within the cell.[23] 
Thus, when the nanoparticles are exposed to acidic environments, as lysosomal 
compartments where the pH can reach values up to 5.0, they suffer a rapid degradation 
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by hydrolysis into free ions (Fe2+/Fe3+) increasing ROS formation. Additionally, the 
released iron can provoke an homeostasis imbalance that induce DNA damage which 
can trigger carcinogenesis, epigenetic events and inflammatory processes.[24] 
Hosseinkhani et al. studied in detail the toxicities of SPION with different surface 
chemistries (COOH and NH2).[25] In this study, the authors found that positively 
charged amino-functionalized particles induced lower cell viability that acid-coated ones 
which exhibit a negative surface. The reasons of this fact are double, on one hand the 
positive surface of the particles induces higher uptake due to the Coulombic attraction 
with the negatively charged cell membrane. On other hand, the presence of amino 
groups on the particle surface provokes lysosomal rupture by proton sponge effect 
releasing the particles into the cytosol together with the lysosomal content enhancing 
their cytotoxicity. As it has been mentioned before, surface coating plays a critical role in 
the SPION toxicity. One of the most employed type of coatings are polysaccharides as 
dextrans which showed no effect in cell viability and functionality in human monocyte-
macrophages at concentrations as high as 1 mg·mL-1 when were employed for coating 
ultrasmall SPION (Ferumoxtran-10).[26]  Pompa et al. have reported that the use of a 
silica shell on the SPION surface significantly reduces the cytotoxicity of the 
nanoparticles mainly due to a decrease in ROS production.[27] Uncoated SPION are 
more susceptible to degradation releasing 2-folds iron to the media which catalyze the 
ROS formation. Additionally, the introduction of amino groups on the silica surface 
provides a higher protection against the acid environment of lysosomal compartments 
reducing even more the iron leakage. Silica coated SPION of 30~40nm have been 
tested in murine models as magnetic resonance imaging (MRI) T1 contrast agents 
providing strong positive signal enhancement in different tissues as heart, liver, bladder 
and kidney without inducing any toxicity in the host.[28] David et al. have evaluated the 
effect in the cytotoxicity of diverse coatings as starch, amino groups and polyethylene 
glycol (PEG) of different chain length (2k, 5k and 20k Da) employing Chinese Hamster 
ovaries (CHO-K1 cells).[29] These authors found that the toxicity was strongly related 
with the particle uptake being the particles decorated with PEG 2kDa the best tolerated 
at concentrations up to 100 µg·mL-1 showing the lower uptake into the cells. Poly(lactic-
co-glycolic acid) (PLGA) a biocompatible polymer widely employed in nanomedicine, 
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has been employed to coat SPION to enhanced their biocompatibility for MRI,[30] drug 
delivery[31] and immune stimulation.[32] Mei et al. have reported that PLGA coating 
prevents autophagosome accumulation within the cell which is a typical source of 
toxicity of metal-based nanoparticles.[33] Proteins have also been used as coatings for 
SPION. As example, Nosrati et al. have employed bovine serum albumin (BSA) as 
biocompatible coating of Fe3O4 nanoparticles for transporting curcumin to breast cancer 
cells inducing potent therapeutic responses.[34] Once the nanoparticles are exposed to 
biological fluids, they are immediately covered by the proteins present in the media 
forming the so-called protein corona. The protein corona is the “readable” part of the 
nanoparticle for the cells and is the responsible of its behavior in terms of cellular 
uptake and potential toxicity. Dawson et al. have studied the protein corona formation in 
SPION coated with citric acid, poly(acrylic acid) and a double layer of oleic acid.[35] 
They found that particles coated with negatively charged moieties (citrate and 
poly(acrylic acid)) form their corona in the first 2 hours whereas particles coated with 
oleic acid requires more time due to the non-covalent nature of the double oleic layer. 
Interestingly, in this last group of SPION, the protein corona is lesser enriched in 
complement and immunoglobulin proteins than the other ones which make them better 
for escape to immune clearance. Protein corona formation is a dynamic process which 
should be studied in detail in order to evaluate the potential fate of the nanoparticle 
within the host. This process depends on different factors which should be considered in 
each case, not only to the nanoparticle surface chemistry; even the slight temperature 
changes provoked by circadian rhythm caused significant variations in the protein 
composition.[36]    
In vitro cytotoxicity evaluation provides valuable information about the safety of these 
particles, but this information should be contrasted with in vivo assays. Employing 
appropriate animal models, biodistribution and realistic toxicity assessment can be 
conveniently studied. The degradation products of SPION, Fe2+ and Fe3+ are generally 
incorporated into iron-storage proteins as hemoglobin, transferrin or ferritin,[37] but the 
toxicity of the nanoparticles should be evaluated for each system because it depends on 
the size, coating and surface chemistry. The biodistribution of SPION once they are 
administered in the blood stream can be determined and quantified by different 
Ac
ce
pte
d M
an
us
cri
pt
 
 
techniques such as MRI, near infrared fluorescence imaging by labelling the 
nanoparticles with the corresponding fluorophore, positron emission tomography (PET) 
through the introduction of radionuclides or single photon emission computed 
tomography (SPECT), among others.[38] Wei et al. reported that carboxyl-coated Fe3O4 
nanoparticles exhibited different organ accumulation depending on their size.[39] The 
smallest nanoparticles (10 nm) were mainly located in the liver whereas the bigger ones 
(40 nm) were located mostly in the spleen. In all the cases, the nanoparticles did not 
induce significant toxicity, but the smallest ones produce an alteration in the genes 
related with oxidative stress in the cell.   Xiao et al. have studied the in vivo distribution 
of SPION in the body are mainly with different sizes (10 and 30 nm) and decorated with 
PEG or polyethylene imine (PEI).[40]  They found that SPION coated with PEI were 
rapidly cleared by macrophages due to the high affinitive of their positively charged 
surface with plasma proteins and exhibited the lower tumoral uptake. Particles of 10 nm 
coated with PEG presented the higher tumoral uptake followed by the bigger particles of 
30 nm. In all cases, SPION were also accumulated in liver and spleen. PEG-coated 
SPION remains during more than two weeks without producing toxicity, only a slight 
increase in alanine-transaminase (ALT) enzyme and inconsequential histopathological 
alterations in these organs. PEI-coated nanoparticles were removed from these organs 
faster, but they produce severe toxicity leading to the animal death when the 
administered dose reached 2.5 mg·kg-1. The high toxicity observed in these 
nanoparticles could be explained by different mechanisms such as cell membrane and 
mitochondrial membrane disruption which provoke apoptosis, higher hemolytic capacity 
due to their positive charge and capillary blockage due to the aggregation tendency of 
positively charged nanoparticles in biological milieu. In a recent study, Wang et al. have 
reported that SPION coated with PEI, which was employed to complex siRNA by 
electrostati  interactions between the positive charges of the polymer with the 
negatively charged phosphate backbone of the oligonucleotide strand, did not induce 
toxicity in rat model.[41] Despite the high accumulation in liver and spleen, these organs 
presented a normal histopathological analysis and similar ALT enzymatic expression 
that controls. Moreover, the administration of these particles did not cause renal toxicity 
in sight of the similar levels of blood urea nitrogen and creatinine with the untreated 
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animals. Therefore, these nanosystems are suitable for the transportation of therapeutic 
oligonucleotides. SPION conjugated with human relaxin-2 (RLX) have been employed 
for the modulation of tumour stroma in the treatment of pancreatic cancer.[42] 
Pancreatic tumors are characterized by presenting high content of cancer-associated 
fibroblasts (CAFs) which form a dense extracellular matrix around the tumour 
hampering the diffusion of chemotherapeutic agents inside the malignancy. In this work, 
the nanosystems were able to reach the tumoral area and once there, to release RLX 
which reduces fibrosis and improves the penetration of chemotherapeutic drugs in the 
tumoral tissue. It is interesting to point out that in the case of antitumoral applications, 
the capacity of SPION to generate ROS can be employed for enhancing the cytotoxic 
effects of certain antitumoral drugs. This is the case of platinum drugs as cis-platin. This 
drug activates nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) 
which generates O2•− that are transformed into H2O2 by the action of superoxide 
dismutase (SOD).[43] Lin et al. have reported the use of iron oxide nanoparticles coated 
with polyethylene imine (PEI) and PEG and loaded with cisplatin(IV) prodrugs in liver 
cancer murine models.[44] These particles induce the generation of H2O2 in the 
cytosolic space by the activation of Pt(IV) drug in the intracellular reductive 
environment. The produced H2O2 was rapidly transformed into highly toxic ROS by the 
action of the released iron causing the tumoral cell destruction (Figure 1). The particles 
were directed to the tumoral lesion by the action of magnetic fields which reduces their 
toxicity in other organs. 
Finally, as another interesting example, SPION clusters coated with the photosensitizer 
photoporphyrin IX (PpIX) have been successfully applied for the activatable destruction 
of tumoral cells by illumination with near infrared radiation (NIR).[45] In this work, the 
photosensitizer acted as SPION cluster coating enhancing its colloidal stability in 
aqueous media and as an activatable drug which generates highly cytotoxic singlet 
oxygen at the same time.  The results showed that these nanoparticles in combination 
with NIR exposition caused 82.60% tumour volume reduction compared with free 
photoporphyrin.  
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3. Gold nanoparticles 
The application of gold nanoparticles (GNP) in the clinic field has received huge 
attention in the recent years due to the unique optical properties in combination with 
their high biocompatibility and lack of toxicity.[46] Colloidal gold has been employed in 
different materials from ancient times being one of the most impressive example  the 
Lycurgus cup which exhibits different colors depending on the incidence light direction. 
Gold nanoparticles exhibit high absorption and scattering of light from the visible region 
(390-650 nm) to near infrared or NIR (650 to 1350 nm). When a metallic nanoparticle, 
as is the case of GNP, is irradiated with light which has smaller wavelength than its size, 
it appears a coherent oscillation of the free electrons present on the surface, a 
phenomenon called surface plasmon resonance (SPR).[47] SPR is highly dependent on 
the size and shape of GNP. Thus, the change in the optical properties of these particles 
depending on their size has been employed for the detection of different 
biomolecules,[48] and even cells,[49] by the colour shift observed as a consequence of 
the aggregation of GNP in the presence of the analyte in each case. Spherical GNP 
presents only one SPR band located in the visible region (around 520 nm) due to their 
symmetry in all axes. In the case of non-symmetrical GNP, as is the case of rod-like 
GNP, a second SPR band appears because there are two different oscillation modes 
along the nanoparticle (longitudinal and transversal). This second band is located at 
higher wavelength and can be tuned by the modification of the length to width relation 
(aspect ratio).  When the aspect ratio of GNP is higher than 2, the second SPR band 
can be placed in the near infrared region (NIR) which is especially valuable because 
living tissues are transparent to this wavelength. Thus, NIR radiation produces the 
excitation of the electrons located on the particle surface that lost the acquired energy 
by heat transfer increasing the temperature in the surroundings. Therefore, this property 
has been widely employed for the selective destruction of tumoral cells by the controlled 
irradiation with NIR in the diseased zone.[50] GNP with diverse sizes and shapes can 
be precisely synthesized employing different techniques such as photochemical,[51] 
electrochemical[52] and perhaps the most used one, seed mediated approach.[53] In 
the last strategy, gold seeds with size around 3-4 nm are produced by reduction of gold 
salts. After this stem, the seeds are added to a solution of gold salts in the presence of 
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a weak redactor and a surfactant, usually cetyl trimethylammonium bromide (CTAB), 
producing the seed growth up to the desired final size and shape depending on the 
conditions employed. CTAB is highly toxic for the cells due to its capacity  to disrupt the 
cellular membrane and therefore it is usually removed from the surface by more 
biocompatible molecules as phosphatidylcholine,[54] polyelectrolyte-based coats[55] or 
polyethylenglycol (PEG) chains.[56] In vitro toxicity of GNP depends on their size, 
shape and surface coating. GNP with size around 1-1.5 nm exhibited the higher 
cytotoxicity, showing an IC50 30-56 µM, in comparison with bigger particles of 15 nm 
which were nontoxic at concentrations 60-fold and 100-fold higher.[57] In a later work, 
the origin of the cytotoxicity of the tinier particles was deeply studied concluding that 
was due to oxidative stress caused by the generation of ROS on the particle 
surface.[58] The high surface/volume ratio of the smallest particles produced the larger 
amount of ROS and therefore, the higher toxicity. Interestingly, the toxicity was avoided 
by surface passivation with thiol-contained antioxidants which confirms the oxidative 
mechanism of cell damage. In any case, particle uptake depends on the cell line and 
should be studied for each situation. GNP of 45 nm were engulfed in higher amount 
than smaller particles of 13 nm in human dermal fibroblast being the uptake mechanism 
different for each case; clathrin-mediated endocytosis for the bigger particles and 
phagocytosis for the smaller ones.[59] The bigger particles exhibited the higher toxicity 
by cytoskeleton disruption due to their higher tendency to escape from the endosomes 
and be accumulated in the cytoplasm. Not only the own size of the nanoparticle present 
strong influence in its cellular uptake and therefore, in the cytotoxicity, but also the 
aggregation state of them. Chan et al. have reported that  have reported that particle 
aggregation reduces the uptake up to 25% in comparison with well dispersed 
nanoparticles in different cell populations.[60] Nanoparticle shape presents a significant 
influence in the cellular uptake. Chan et al. studied the effect of size (1-100 nm) and 
shape (1:1 to 1:5 aspect ratio) stabilized with citrate in particle uptake employing HeLa 
cells.[61] The authors reported an optimal size around 50 nm and aspect-ratio (1:1) 
which exhibited the higher uptake whereas the uptake was lower in the case of rod-like 
particles. More exotic shapes as nanotriangles[62] or nanostars[63] have presented 
significant lower cytotoxicity than the corresponding spheres at the same 
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concentrations. Surface charge is another parameter which exerts influence in the GNP 
cytotoxicity. Hussain et al. have compared the effect of GNP positively, negatively 
charged or neutral in the viability of human keratinocyte cell line (HaCaT).[64] Neutral 
nanoparticles presented the lower toxicity while charged ones (both positive and 
negative) induced higher amounts of cell alterations as mitochondrial stress, DNA 
damage and apoptosis induction by expression of caspase-3. Liver is the main organ on 
charge of blood detoxification and it is well reported that practically all nanoparticles are 
accumulated there.[65] Monteiro-Riviere et al. have studied the cytotoxicity in human 
hepatocytes which induce GNP covered with polymeric coatings as branched 
polyethylenimine (BPEI), lipoic acid (LA) polyethylene and glycol (PEG) as a model of 
positive, negative and neutral coatings.[66] BPEI nanoparticles were found toxic for the 
cells at concentrations around 50 µg·mL-1, mainly by the induction of persistent ROS 
production, whereas the other ones were non-toxic. Interestingly, the toxic effect could 
be completely avoided by the previous incubation of the nanoparticles with human 
serum albumin (HSA) which form a protein corona around the particle which reduces 
the particle uptake in the hepatocyte and the oxidative stress inside the cell. As is was 
mentioned in the case of SPION, the in vitro evaluation of the toxicity provides important 
information but does not guarantee the safety of a certain treatment based on 
nanoparticles. Obviously, the toxicity and biodistribution of a nanoparticle in in vivo 
models depends on the administration route and should be considered in each 
case.[67] For in vivo applications, the particle surface must be decorated with 
biocompatible moieties which maintain the colloidal stability of GNP in physiological 
media. Glutathione-coated GNP of 1-2 nm were injected subcutaneously at different 
concentrations showing excellent biocompatibility.[68] The particles were cleared during 
the first week by the kidneys and after this time, by the liver, without inducing any 
significative alterations in these organs. GNP coated with a silica shell decorated with 
PEG chains have also been employed for in vivo imaging by Raman spectroscopy 
without provoking cytotoxicity through intravenous and rectal administration in rat 
models.[69] The toxic effect and biodistribution of citrate-coated GNP of 12 nm after 
three repeated intraperitoneal administration during 8 days at different concentrations 
(40, 200, and 400 µg·kg-1·day-1) were evaluated.[70] Gold content was measured in 
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blood and tissues by atomic absorption and inductively coupled plasma-mass 
spectroscopy showing that gold content in blood did not increase in proportion to the 
dosage. This fact indicated that gold accumulation was produced mainly in the organs, 
being liver, kidney and spleen the organs which retained higher gold amounts and brain 
the lower. Importantly, gold administration in all cases did not lead to any mortality, 
none of the organs showed any histological alterations and the biochemical and 
haematological analysis presented normal values. Villaverde et al. have encapsulated 
gold nanorods inside mesoporous silica nanoparticles loaded with doxorubicin and 
coated with a thermosensitive polymer to prevent the premature drug departure (Figure 
2).[71] The external surface of these nanocarriers was decorated with a specific peptide 
(Napamide) in order to enhance their uptake in melanoma cells. In this system, gold 
nanorods were employed as activatable heaters under NIR radiation. Under light 
exposition, the temperature in the surroundings exceeded the transition temperature of 
the polymeric coating which suffered a collapse releasing the cytotoxic drug trapped 
within the silica network. Thus, this system was able to induce a potent cytotoxic 
response in melanoma cells exposed to NIR whereas was lesser toxic for fibroblast 
cells used as control.  
Parak et al. have studied the fate of the organic surface coating after injection in mice 
grafting a polymer poly(isobutylene-alt-maleic anhydride)-graft-dodecyl labelled with a 
radioactive isotope 111In on the gold surface.[72] Inorganic core was synthesized using 
198Au in order to trace the fate of the gold nuclei in the host. The results indicated that 
the inorganic cores were retained in the liver whereas the polymeric shells were 
excreted through the kidneys. In vitro evaluation employing HUVEC and Kupffer cells 
showed that the nanoparticles were retained in endosomes and lysosomes and the 
polymer shell was degraded by proteolytic enzymes present in these organs. Rengan et 
al. have encapsulated GNP within liposomes of 100 nm of diameter achieving the 
complete ablation of the tumoral mass in a fibroblast (HT1080) tumour xenograft model 
using NIR laser irradiation at 750 nm.[73] As in the previous case, these liposomes 
were mainly accumulated in liver, spleen and kidneys but they did not induce any sign 
of acute toxicity in these organs. Only the tumoral region which was exposed to NIR 
light suffered an extensive necrotic response which leads to complete tumour relapse. 
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Encapsulation of therapeutic agents into exosomes has revealed as a promising 
strategy for the selective transportation of cargo to diseased tissues.[74] Exosomes are 
extracellular vesicles secreted by cells which have been used for the delivery of 
sensitive payloads as oligonucleotide strands or proteins. This strategy combines the 
advantage of the use of soft coatings, like liposomes, which are perfectly biocompatible 
and provides outstanding colloidal stability with the targeted delivery of cargo thanks to 
the presence of specific receptors located on the surface of these biological moieties. 
Betzer et al. have encapsulated glucose-coated 5 nm GNP for imaging brain damage in 
a ischemic stroke mouse model.[75] The intranasal administration of these particles 
lead to their accumulation in the damaged lesion of the brain providing a non-invasive 
approach for the visualization of brain pathologies. In the case of thermal ablation of 
tumoral cells which employs GNP as heat source under NIR radiation, one of the main 
limitations is that only spherical particles which sizes higher than 50 nm presents strong 
NIR absorption. Larger nanoparticles present the lower penetration in living tissues due 
to their hampered diffusion. Gao et al. have reported an interesting work in which small 
GNP decorated with PEG chains functionalized with aziridine groups suffered controlled 
aggregation under laser excitation at 405 nm by covalent cross-linking with the resulting 
carbene formed by the light exposition.[76] After 15 min of light exposition, the 
aggregation cause the apparition of a strong NIR absorption band at 700-900 nm. This 
phenomenon was reproduced in a tumour-bearing murine model yielding to a significant 
tumour shrinkage and extended life expectancy of the mice exposed to both light 
treatments, 405 nm for inducing the aggregation and 808 nm irradiation for enhancing 
the temperature in the tumoral tissue.   
 
4. Graphene 
Graphene consists in a hexagonally-arranged two-dimensional network of sp2-
hybridized carbon atoms.[77] Graphene is being thoroughly investigated for several 
biomedical applications (drug and gene delivery, biosensing and imaging, among 
others) due to its outstanding properties, such as electronic and thermal conductivity, 
high surface area and mechanical strength.[77] However, one of the main limitations of 
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unmodified graphene for biomedical application is the difficulty in obtaining stable 
aqueous suspensions, which is necessary in the biological context. For this reason, 
graphene oxide (GO) is commonly employed for biomedical applications, since a stable 
suspension of GO in aqueous medium can be obtained through hydrogen bonding.[78]  
The toxicity of graphene-based materials has been a matter of discussion in recent 
years, since many parameters appear to deeply affect their biocompatibility.[79–82] In 
healthy human lung cells, graphene toxicity was seen to depend on concentration and 
exposure time.[83] Mitochondrial injury in PC12 neuronal cells was seen to be dose and 
shape-dependent.[84] Also in PC12 cells, reduced GO (rGO) toxicity was mediated by 
an increase in caspase 3 activation, generation of ROS  and release of lactate 
dehydrogenase (LDH), while it was shown to be less toxic than carbon nanotubes.[85] 
GO toxicity in A549 cells due to oxidative stress was also dose and size-dependent, 
despite showing low uptake.[86] Graphene has also been observed to be able of 
causing DNA damage.[87] Modification of particle surface has been thoroughly 
employed to improve the biocompatibility of graphene-based materials, with PEGylation 
as the most widely used strategy.[78] In fact, PEGylation has been shown to improve 
the in vitro biocompatibility of graphene in a wide variety of cell lines.[78,88–91] 
Regarding their hemocompatibility profile, while hemolysis was insignificant for both 
graphene and GO in some studies,[92] other authors appear to have found both 
hemolytic and thrombotic potential in these materials.[93,94] Some data indicate that 
both effects might be dependent on morphology as well as chemical structure.[78] For 
example, GO modification with amino groups [93] or coating with chitosan eliminated its 
hemolytic effect.[95]  
Several studies have also been performed to study the toxicity of graphene-based 
structures in vivo. Different authors have found pulmonary toxicity after intravenous 
administration of GO and BSA-capped graphene, perhaps linked to the thrombogenic 
potential mentioned above.[96–99] On the other hand, graphene administration did not 
affect survival rate of zebrafish embryos.[100] No toxic effects (neither in longevity nor 
reproductive capacity) were observed after administration in Caenorhabditis elegans 
nematode either.[101] When testing GO and PEGylated Poly-L-Lysine (PEG-PLL)-
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modified GO in C. elegans, Zhang et al. observed that, while the materials were not 
toxic under normal conditions, severe toxicity was observed under oxidative stress 
induced by juglone (Figure 3).[102]  
This study highlights the importance of taking into account not just the material structure 
and composition, but also the ongoing physio-pathological context, since this can 
deeply affect its biological behavior. The preparation method of graphene derivatives 
can also significantly modify their behavior. Green synthesis strategies being proposed 
to decrease the toxicity of these materials. As a few examples, reduction of GO with 
ascorbic acid, stabilization of rGO with L-tryptophan and the use of reducing sugars 
such as glucose and fructose have been proposed.[103–105] While obtaining magnetic 
graphene-derived materials, Urbas et al. observed that the employed chemical 
functionalization of GO and Fe3O4 also enhanced the biocompatibility of the 
material.[106] Graphene quantum dots were seen to be well tolerated in vivo, and easily 
excreted in urine thanks to their small size.[107] Thickness of functionalized graphene 
oxide sheets has been shown to play a critical role in tissue accumulation and urinary 
excretion, with the thinner GO sheets being mainly excreted through urine and with a 
larger fraction of the thicker GO sheets remaining mainly in the spleen and liver 24 h 
after intravenous injection.[108]  
Yang et al. showed that PEGylated graphene did not induce any adverse toxic effects in 
mice.[109] This indicates that, although graphene is not biodegradable, coating with 
hydrophilic polymers can enhance its in vivo biocompatibility.[110] PEGylated graphene 
showed no absorption after oral administration with almost complete excretion.[111] 
Intraocularly administered GO was well tolerated.[112] Upon intraperitoneal injection, 
PEGylated GO was seen to accumulate in liver and spleen. [78,111] Besides 
PEGylation, graphene surface modification with other polymers has also been proposed 
to improve its biocompatibility.[113] Modification of GO with dextran improved its 
stability in suspension (Figure 4), while it also enhanced its biocompatibility with HeLa 
cells.[114] Modification of GO with Poly(amido amine) (PAMAM) dendrimer enhanced 
aqueous dispersibility and produced a hybrid material with almost no toxicity towards 
MDA-MB-231 cells, although the PAMAM dendrimer alone did show some toxicity for 
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the same cells.[115] Modification of GO with pluronic F127 greatly enhanced 
dispersibility, although in this case the modified material did show some toxicity in 
vitro.[116] Polydopamine-modified rGO had ultralow hemolytic potential and exhibited 
very low toxicity towards HUVEC cells.[117] Xu et al. have suggested that graphene 
functionalization with poly(acrylic acid) (PAA) could be an alternative to PEGylation with 
better performance in improving in vitro and in vivo biocompatibility.[118] 
  
5. Mesoporous silicon nanoparticles (MSiNs) 
MSiNs possess a semicristalline network and present inherent luminescence with a 
broad excitation band and narrow emission (tipically in the NIR region).[119,120] This 
characteristic makes them specially interesting for the development of theranostic 
nanomaterials, in which real time follow-up by optical methods can be carried out while 
the particles are carrying out their therapeutic function. Furthermore, their mesoporous 
structure provides them with large surface areas (200-500 m2/g) that enable loading 
considerable amounts of drugs.[120] MSiNs can be prepared by a top-down or a 
bottom-up approach[119], being the pore structure highly dependent on the fabrication 
conditions. In order to stabilize the surface of as-prepared MSiNs, different 
modifications routes are followed, being the main ones oxidation, hydrocarbonization, 
carbonization, silylation and silanization.[120] Further chemical modifications can be 
performed to allow stimuli-responsive or other forms of controlled drug release. 
[121,122] 
MSiNs are generally considered to be safe, as the silicon network is known to easily 
degrade into non-toxic products (mainly related to silicic acid), which can be then safely 
excreted.[120] In an excellent review article, Croissant et al. described the different 
parameters that have been seen to affect this degradation behavior.[119] A deep 
understanding of the parameters that can regulate the dissolution kinetics would enable 
the development of safer and more effective nanotherapeutics. For example, while 
nanoparticle size is thought to play only a minor role in the degradation kinetics[119], 
their porosity is a key parameter, with particles with larger pores having faster 
dissolution kinetics.[119,123–125] Oxidation of the MSiN surface, as well as coating 
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with a silica layer, are known to slow down the dissolution process.[126] MSiN coating 
with dextran improved the stability of the nanoparticles against dissolution, enabling 
longer-term particle tracking.[127] Covalent attachment of PEG on the surface of MSiNs 
also slowed down particle degradation, with decreasing degradation rate as the polymer 
molecular weight was increased.[123] The medium in which the MSiNs are dispersed 
greatly influences dissolution, with accelerated degradation in protein-containing 
medium [128] and in basic environments [123]. In the biomedical context, the changing 
environment to which the nanoparticles will be exposed can also be of great 
importance, not just in the context of pH, since both intra- and extracellular 
environments contain a complex mixture of different biomolecules. In this context, 
almost complete biodegradation of MSiNs inside MCF-17 breast cancer cells was seen 
after 13 days, as evaluated by Raman micro-spectroscopy.[129] Tzur-Balter et al. also 
demonstrated that MSiN in vitro and in vivo degradation was accelerated with higher 
concentration of ROS, conditions that can be found in different pathological 
conditions.[130] 
Different studies have been performed regarding MSiN biocompatibility in vitro. For 
example, no toxicity could be seen in endothelial cells in vitro, neither before nor after 
modification of MSiNs with RGD peptides.[131] However, modifications on the material 
structure and composition can alter their toxicity. The effect of surface properties of 
MSiNs on their biocompatibility was thoroughly evaluated by Shahbazi et al.[132] They 
found that MSiN toxicity is more dependent on surface charge than on their 
hydrophobicity/hydrophilicity, being the aminopropyl-functionalized MSiNs the most 
toxic, and negatively-charged MSiNs the least toxic for the studied cells.[132] 
Aminopropyl- and undecylenic acid-functionalized MSiNs were also seen to produce the 
largest amount of hemolysis.[132] When cultured with macrophages, PEGylated MSiNs 
were also shown not to induce the release of proinflammatory cytokines.[123] In vivo 
evaluation of these same materials correlated well with the toxicity observed in vitro, 
showing no significant changes in biochemical or hematological parameters, although 
some mild effects were appreciated in kidneys, liver and spleen.[132] Ivanov et al. 
showed that MSiNs presented a good biocompatibility profile in vivo after intravenous 
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injection, with a significantly reduced number of foreign body-type granulomas 
compared to animals injected with mesoporous silica nanoparticles.[133]  
The main strategies employed to improve the in vivo performance of MSiNs are based 
on chemically decorating the particle surface. Hydrophobin-functionalized MSiNs 
showed improved dispersability in plasma (due to their increased hydrophilicity), and 
reduced the amount of particles trapped in the lung after IV injection, increasing also the 
liver-to-spleen ratio of coated particles compared to non-coated ones.[134] On the other 
hand, similar Hydrophobin-functionalized MSiNs administered orally were observed not 
to cross the intestinal wall, and to present extended transit time in the gastrointestinal 
tract, due to their mucoadhesion in the stomach.[135] Poly(methyl vinyl ether-co-maleic 
acid) (PMVE-MA)-grafted MSiNs showed also improved colloidal and plasma stability 
through charge repulsion.[136] Surface modification with BSA reduced non-specific 
cellular uptake in vitro and prolonged circulation time in vivo.[137] In healthy animals, 
dextran-modified MSiNs were seen to accumulate mainly in the liver, where they were 
slowly degraded when compared to non-modified MSiNs.[127]  
 
6. Mesoporous silica nanoparticles (MSNs) 
MSNs are constituted by an amorphous silicon oxide network with porosity in the 
mesopore range (2-50 nm in diameter). Their high surface area (around 100 m2/g) 
enables loading large amounts of drugs, and their easy chemical modification by silanol 
chemistry allows for the development of highly efficient multifunctional stimuli-
responsive drug delivery systems.[138–143] Many different types of therapeutic agents 
can be housed inside the silica matrix and their release can be triggered at demand 
anchoring different stimuli-responsive gatekeepers on the nanoparticle surface.[144] 
Thus, MSN have been engineered to release the payload in response to external stimuli 
as light,[145,146] magnetic fields[147–149] and ultrasounds,[150] or internal stimuli, 
characteristic of the pathology treated, as pH,[151] presence of enzymes[152] or redox 
changes,[153] among others. Regarding one of their main limitations, although colloidal 
stability of unmodified MSNs is challenging, Lin et al. showed that PEGylation could 
provide MSNs with long term stability in different media at physiological temperature, 
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while also enhancing their biocompatibility and reducing their uptake by 
macrophages.[154] PEGylation has therefore become a widespread process in the field 
to improve this parameter.  
Silica nanoparticles are generally considered to have a good biocompatibility profile, 
although some inconsistencies between in vitro and in vivo data have been found.[155]  
Many parameters are known to affect the toxicity of silica nanoparticles in vitro, such as 
their size, dose and cell type.[156] Kim et al. showed in a microfluidic setup that 
unmodified MSNs present a flow-dependent toxicity in human endothelial cells, while 
PEGylated MSNs did not show relevant toxicity, neither under static conditions nor 
under flow.[157]  When evaluating the immune response towards cargo-free MSNs in 
primary immune cells, Heidegger et al. observed only a very low immune response as 
determined by the release of inflammatory cytokines.[158] Lin et al. showed that non-
porous silica nanoparticles induced a larger degree of hemolysis than MSNs (Figure 
5).[159] Moreover, Slowing et al. showed that PEGylation of MSNs further reduced their 
hemolytic activity.[160] Urata et al. also proved that the introduction of ethenylene-
bridged silsesquioxanes into MSNs could also reduce their hemolytic activity without the 
need for PEGylation.[161]  
Liu et al. showed a very good safety profile of Hollow-MSNs (HMSNs) in vivo, both after 
single and repeated injections (up to 4 injections were performed per mouse).[162] 
Additionally, they observed that all of the injected dose on HMSNs had been excreted 4 
weeks after injection.[162]  Fu et al. evaluated the safety profile of MSNs after 
administration by different routes.[163] They found that systemic distribution after 
hypodermic and intramuscular administration was almost negligible, and that the 
particles were well tolerated and had good tissue biocompatibility even after oral or 
intravenous administration.[163] Hudson et al. also analyzed the in vivo biocompatibility 
of mesoporous silica materials with sizes between 150 nm and 4 µm, and with varying 
pore sizes after subcutaneous, intraperitoneal and intravenous administration in 
mice.[164] Materials that had been injected subcutaneously showed good, and the 
material was progressively degraded over three months. However, severe toxicity was 
observed after intraperitoneal and intravenous injection.[164] Lung tissue evaluation 
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showed that the toxicity was likely due to thrombosis. We should take into account that 
the materials employed here were not PEGylated and lacked any other kind of surface 
modification that could prevent aggregation in vivo, and that the doses employed (30 
mg/animal) could be considered as large when compared to the amounts of particles 
employed in other studies.[165,166] Yu et al. also found that particle porosity and 
surface characteristics altered the toxicological profile in vivo.[167] In this study, they 
found that the maximum tolerated dose was highest for non-porous silica, followed by 
amino-functionalized MSNs and the worst safety profile was seen for non-functionalized 
MSNs. The authors noted that the main cause for the adverse reactions observed was 
the mechanical obstruction of the vasculature due to nanoparticle aggregation in the 
bloodstream.[167] Lee et al. also compared the in vivo toxicity of MSNs and non-porous 
silica nanoparticles and observed a larger dysregulation of spleen function when MSNs 
were injected.[168] The authors highlighted the lack of consistency with in vitro data, 
which had shown a better safety profile for MSNs. Ivanov et al. showed that while small 
(13 nm in diameter) MSNs were generally well tolerated, some foreign body-type 
granulomas in liver spleen as well as liver microgranulation could be seen after 
intravenous injection in mice.[133] Li et al. showed that a PEGylated mesoporous silica 
nanorattle showed very low systemic toxicity in healthy mice.[169] PEGylation or other 
strategies aimed at decreasing the possibility of particle aggregation appear therefore 
as critical for the safe use of MSNs with systemic distribution. 
One of the main concerns regarding inorganic nanoparticle toxicity is the possibility for 
bioaccumulation of the employed nanoparticles, especially after repeated 
administration. To prevent chronic toxicity associated with bioaccumulation, the 
employed nanoparticles should be biodegraded and/or excreted by some elimination 
route in a reasonable time frame after they have exerted their function. MSNs 
decompose in physiological environments, giving rise to soluble silicon species like 
monosilicic acid, which can be excreted in urine (Figure 6).[119,138,170]  
Several factor have been seen to regulate MSN solubility in vitro. MSN dissolution rate 
depends on the medium in which they are, with faster dissolution in simulated lung fluid 
(SLF) than in simulated body fluid (SBF) or phosphate buffered saline (PBS), and with 
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the slowest release happening in simulated gastric fluid.[171] Braun et al. as well as 
Yamada et al. have observed that the dissolution kinetics of MSNs in vitro are generally 
independent of particle size.[171,172] Hao et al. saw that the degradation of MSNs in 
medium with fetal bovine serum (FBS) was dependent on nanoparticle morphology, with 
slower dissolution kinetics for rod-shaped MSNs than for spherical particles.[173] 
Townley et al. al showed that nanoparticle surface area is directly related to dissolution, 
with faster kinetics for MSNs with larger surface areas.[174] Particle composition also 
greatly affects dissolution kinetics, both when functionalized on their external surface 
(seeing that phenyl-functionalization accelerates dissolution the most)[175], with 
different dopings (Ca- and Mn-doping accelerate dissolution [176,177], while zirconia-
doping slows it down[178]), or with the inclusion of breakable bonds within the silica 
network (the inclusion of S-S bonds would accelerate particle dissolution in reducing 
environments[179,180]). Cauda et al. showed that PEGylation significantly slowed down 
the dissolution of MSNs, also as a function of the coverage density and the molecular 
weight of the polymer[181]. This finding was further confirmed by  Hao et al. [173], and it 
has also been seen to be true for the presence of other polymers grafted on MSN 
surface[150]. The method used to produce the MSNs can also have a critical impact on 
the dissolution kinetics. Shen et al. showed that, by preparing the particles with a 
biphase stratification approach, they could obtain 3D-dendritic MSNs for which their 
simulated biodegradation could be tuned to be complete in just 24 h (compared to 2 
weeks for more traditional architectures).[182]  Möller et al. recently described the 
systematic evaluation of dissolution kinetics of MSNs with different functionalities 
prepared at acidic, neutral or basic pH following a common recipe.[183] Their findings 
show that the dissolution at low concentrations is mainly directed by the silica network 
connectivity and the silica building blocks, with MSNs with interrupted networks 
prepared under basic conditions degraded the fastest (almost completely within a few 
hours). Surprisingly, additional disulfide linkers in the pore walls retarded this process, 
which the authors ascribed to the hydrophobicity of such linkers.[183] 
Regarding the biodegradation behavior of MSNs in vivo, Zhang et al showed that after 
injection in mice, most of the administered dose of PEGylated and folic-acid targeted 48 
nm-MSNs could be safely excreted from the animal body.[184] He et al. evaluated the 
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biodistribution of MSNs of different sizes (80-360 nm) with or without PEGylation, and 
their results show that PEGylated smaller particles escape more easily from liver and 
spleen, and are degraded mores slowly as a consequence.[185] No toxicity was 
observed up to 1 month after injection for any of the MSNs tested.[185] The shape of 
MSNs has also been shown to affect nanoparticle biodistribution and elimination routes. 
Short rod-shaped MSNs were found to be trapped more efficiently by the liver, 
compared to the larger presence of long rod-shaped MSNs, which were found more in 
the spleen.[186] In that study, MSN clearance was also found to be faster for the short 
rod-shaped particles, through the two main excretion routes seen (in urine and feces). 
MSNs here did not cause significant toxicity in vivo, although some biliary excretion and 
glomerular filtration dysfunction could have been induced.[186] Nanoparticle shape has 
also been shown to affect biodistribution of orally-administered MSNs, with particles 
with larger aspect ratios presenting decreased biodegradation, systemic absorption and 
especially, reduced liver distribution and excretion in urine.[187]  
 
6.1 Protocells 
As it has mentioned along this section, mesoporous silica is an excellent material for 
drug delivery due to its extremely high loading capacity and excellent biocompatibility, 
and the possibility of developing a wide variety of stimuli-responsive nano-DDS. Despite 
the efficacy showed by these smart nanocarriers, the introduction of complex 
gatekeepers complicates the translation to the clinic of these systems. A Protocell is a 
nanosystem composed by a mesoporous silica core coated with a lipid bilayer which 
avoids the premature drug departure until the system enters into the target cells and 
provides astonishing colloidal stability to the system in aqueous environments.[188] 
Additionally, lipophilic drugs can be transported within the lipidic shell enhancing even 
more the cargo capacity of these nanocarriers.[14] The external surface of protocells 
has been decorated with targeting moieties in order to provide selectivity against the 
target cells. As an example, Rosenholm et al. have attached folic acid on the protocell 
surface to deliver zoledronic acid (ZOL) specifically to breast cancer cells in a murine 
tumour-bearing model of this pathology.[189] ZOL is a nitrogen-containing 
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bisphosphonate which is widely employed in bone pathologies, but it also induces 
apoptosis in tumour cells and inhibits their growth. However, this drug is rapidly 
excreted and therefore, its application in antitumoral therapy requires an efficient 
transport mechanism. In this work, ZOL was transported to tumoral cells which engulfed 
the protocells due to the overexpression of folate receptors on their membrane 
suppressing the tumour growth and angiogenesis and avoiding the accumulation of ZOL 
in bone tissues. Recently, Mantilla et al. have decorated the external surface of 
protocells with the atoxic subunit B of the cholera toxin which binds to ganglioside GM1 
receptor present on the neuron membrane.[190] This system has been able to deliver 
cargo molecules specifically to motoneurons without affecting the adjacent muscular 
cells. Not only small drugs can be transported by these protocells but also big 
macromolecules as siRNA,[191] ricin toxin[192] and even magnetic nanoparticles.[193] 
The lipid bilayer can be anchored on the MSN surface employing sensitive bonds in 
order to provide stimuli-responsive behavior in the drug departure process. Thus, Wang 
et al. have decorated the external surface of MSN with dithiol bonds which retain the 
lipid bilayer by hydrophobic interactions until the system reaches the inner cellular 
space.[194] Once the particle arrives there, the presence of glutathione induces the 
rupture of the dithiol bond releasing the lipidic shell and therefore, allowing the drug 
departure. One of the main limitation of nanoparticles is their poor tissue penetration, 
which is especially aggravated in the case of tumoral tissues because they are denser 
than healthy ones. This fact hampers even more the navigation of the nanoparticles 
within the malignancy reducing their effect to the tumoral periphery. Villegas et al. have 
described a promising strategy to overcome this limitation.[195] In this work, polymeric 
nanocapsules which contains collagenase, a proteolytic enzyme which digest the 
collagen present in the extracellular matrix softening the tissue, were anchored on the 
surface of the protocells. These nanocapsules were engineered to release the enzyme 
when the pH dropped to mild acidic conditions (pH around 5.5) which is a common 
condition in tumoral tissues. Therefore, when this nanosystem arrived to tumoral tissue, 
the presence of the acidic environment triggered the collagenase release and then, 
these proteolytic enzymes digested the ECM provoking a higher penetration of the 
protocell into the tumoral tissue.   
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6. Expert opinion 
The use of nanoparticles as drug delivery carriers has been widely explored in the last 
decades. Nowadays, a large arsenal of nanocarriers is available thanks to the effort 
carried out by many research groups along the world, from soft nanodevices as 
liposomes, polymersomes or polymeric micelles to rigid structures as is the case of 
metallic or ceramic-type nanoparticles. Among this vast collection, inorganic 
nanocarriers present unique characteristics which have been exploited for the delivery 
of therapeutic agents housed inside their hard matrix or on the surface. Different 
strategies have been developed to achieve a controlled drug release in response to 
certain external or internal stimuli, avoiding the apparition of side effects which are 
common when these drugs are administered in free form. Inorganic nanocarriers 
present high chemical and mechanical stability due to the strong nature of the bonds 
which compose their matrices. This property is especially important in the transportation 
of sensitive molecules such as proteins, small siRNA or labile molecules which can be 
housed inside the porous matrix of mesoporous silica or porous silicon. On contrary, the 
rigidity of these nanoparticles pr sents also important drawbacks. One of the most 
important one is their poor penetration in tumoral tissues. As it has been mentioned 
above, the lymphatic vessel collapse causes the retention of nanoparticles during long 
periods of time. Moreover, the impaired drainage system also increases the interstitial 
pressure in the malignant tissue which strongly compromises the diffusion of the 
nanoparticles within the tissue. This effect is even more severe in the case of rigid 
nanoparticles which cannot alter their form to navigate throughout the usually dense 
tumoral microenvironment. This important liability would be solved anchoring proteolytic 
enzymes on the nanocarrier surface, as was mentioned above,[195,196] or employing 
ultrasounds for propelling them deep inside the solid tumor.[6] Another interesting 
alternative to the poor penetration problem consists of the employment of bacteria as 
nanoparticle carriers.[197] Therefore, due to the self-propelled behavior and sensing 
Ac
ce
pte
d M
an
us
cri
pt
 
 
capacities of bacteria, the nanoparticles can be transported to inner zones of the tumor 
and once there, to release the payload achieving a significant therapeutic enhancement. 
This last strategy is certainly promising because allow to combine the effect of the 
released drugs with the immunogenic nature of bacteria which would trigger an efficient 
immune response capable to destroy the tumoral mass. As it has been widely described 
along the manuscript, inorganic nanoparticles present low degradation rates, especially 
in the case of SPION and gold nanoparticles. The biological behavior of these particles 
can be improved by employing different surface modifications or biocompatible coatings 
(summarized in Table 1) and other strategies mentioned above. However, it is 
necessary to carry out long term in vivo assays which provide information about the 
toxicity issues related with the exposition to these nanodevices during long periods of 
time.  
Regarding this degradability issue, it has been generally accepted that nanomaterials 
employed in biomedical applications should be either biodegradable or at least 
somehow excretable, in order to prevent undesired toxic effects deriving from their 
bioaccumulation. Therefore, biodegradable inorganic nanomaterials, such as MSiNs 
and MSNs could, in principle, hold great promise for drug delivery, since their 
degradation products will be eventually removed from the body in a safe way. The 
parameters governing this dissolution have been therefore thoroughly studied, and a 
wide variety of design and synth sis strategies have been developed to tailor material 
dissolution to the target application and administration route. However, we have also 
discussed here that in some cases, such as SPION, the degradation of the material can 
actually lead to increased toxicity (by increasing ROS generation in this case), and 
different modification or coating strategies are employed to tackle this issue. The recent 
approval of Hensify® (NBTXR3) for the treatment of soft tissue sarcoma in the 
European market also challenges the conventional reasoning that non-degradable 
nanostructures are not suitable for biomedical use.[198] NBTXR3 is composed of 
crystalline hafnium oxide (HfO2) nanoparticles that are not degradable and act by 
amplifying the localized killing effect of radiotherapy. This particles are designed for one 
single intratumoral injection before radiotherapy, and the particles remain in the area 
after the treatment is over. The current evidence seems to indicate that the subsequent 
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presence of these non-degradable particles in the injection site does not induce any 
evident signs of toxicity. Consequently, it is possible that, for applications in which a 
single injection could be enough, non-biodegradable nanoparticles could still constitute 
a helpful tool in therapeutic interventions. However, for applications for which repeated 
administrations are necessary (as is the case for most drug delivery strategies), 
biodegradability and safe excretion of the employed nanostructures will still be 
necessary to ensure that no long-term toxicity arises from excessive bioaccumulation.  
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Figure 3. Schematic representation of stress‐induced toxicity of graphene oxide on 
Caenorhabditis elegans. This image is used without modifications from reference 96. 
Copyright © 2012, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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Figure 4. Suspension stability of GO and dextran-coated GO in different media. This 
image is used without modifications from reference 98. Copyright © 2011, Elsevier.  
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Figure 5. Hemolysis assay for non-porous silica nanoparticles (red line) and MSN 
(green line), water as positive control (blue line) and PBS as negative control (black 
line). The materials were suspended at 60 (a) and 100µg mL−1 (b). Samples were 
centrifuged to detect the presence of hemoglobin (red color) in the supernatant. This 
image is used without modifications from reference 160. Copyright © 2009, WILEY-VCH 
Verlag GmbH & Co. KGaA, Weinheim. 
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Table 1. Summary of the strategies based on nanoparticle surface modification presented in this review, 
Nanoparticle Surface modification Effect  Refs 
SPION Cationic groups Increase cytotoxicity by higher cellular uptake and lysosomal 
rupture 
20, 25 
 Polysaccharides Scarce toxicity even at concentrations up to 1 mg·mL-1 26 
 Silica Increased biocompatibility by lower production of ROS 
within the cell. Improved resistance to degradation. 
27, 28 
 PEG Reduced toxicity by lower cellular uptake 29 
 PLGA Prevent autophagosome accumulation 33 
 PEI Rapid clearance from the blood stream by macrophages and 
high toxicity caused by hemolysis and 
mithocondria/membrane cell disruption. 
40 
GNP Thiol-contained 
antioxidants or gluthatione 
Reduced toxicity by the elimination of ROS 58, 68 
 Branched PEI High toxicity at concentrations of 50 µg·mL-1 66 
 Negative and neutral 
coatings: Lipoic acid, 
citrate or PEG 
Low toxicity in vitro and in vivo 66, 70 
 Silica Low toxicity in vivo 69 
 Silica coated with 
PolyNIPAM 
Low toxicity in vitro 71 
 Liposomes and exosomes Low toxicity in vivo 73, 74 
Graphene Amino groups Reduction in hemolytic and thrombotic potential 93 
 BSA Reduction in hemolytic and thrombotic potential 96-99 
 PEG Improved colloidal stability and biocompatibility 78, 88-91, 102, 
109-112 
 Dextrans Improved colloidal stability and biocompatibility 114 
 PAMAM dendrimers Low toxicity in vitro 115 
 Pluronic F127 Significant toxicity in vitro 116 
 Polydopamine Ultralow hemolytic potential and low toxicity 117 
 Polyacrylic acid Low in vitro and in vivo toxicity 118 
Mesoporous Silicon Cationic groups High toxicity and hemolytic potential 132 
 Silica Increase degradation time, low toxicity 126 
 Dextran Increase degradation time, low toxicity 127 
 PEG Increase degradation time, low toxicity 123, 132 
 Hydrophobin Improved dispersibility in plasma reducing lung 
accumulation 
134, 135 
 PMVE-MA Improved colloidal and plasma stability 136 
 BSA Reduced cell uptake/improved circulation lime 137 
Mesoporous Silica PEG Increase colloidal stability and circulation time. Low toxicity 
and hemolytic potential. Enhanced degradation time. 
154, 157-159, 169, 
181, 184, 185 
 Ethenylene-bridged 
silsesquioxanes in network 
Reduced hemolytic potential 161 
 Calcium, manganese or 
breakable groups as doping 
agents 
Accelerated degradability 176, 177, 179, 180 
 Zirconia doping Delayed degradability 178 
 Lipid bilayers (Protocells) Increased colloidal stability and biocompatibility 188-195 
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and the effect associated with each modification.  
 
 
 
 
 
 
